Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form

Structure

Volumn 23, Issue 4, 2015, Pages 677-687

  Parker, Matthew W ^a   Linkugel, Andrew D ^a,b   Goel, Hira Lal ^c   Wu, Tingting ^a   Mercurio, Arthur M ^c   Vander Kooi, Craig W ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; NEUROPILIN 2; NEUROPILIN-2, HUMAN; PROTEIN BINDING; VASCULOTROPIN C;

AMINO ACID SEQUENCE; BINDING SITE; CHEMISTRY; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN DEGRADATION; PROTEIN MULTIMERIZATION;

AMINO ACID SEQUENCE; BINDING SITES; HUMANS; MOLECULAR SEQUENCE DATA; NEUROPILIN-2; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEOLYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84926466448     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2015.01.018     Document Type: Article

References (69)

1. R.H. Adams, M. Lohrum, A. Klostermann, H. Betz, and A.W. Puschel The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing EMBO J. 16 1997 6077 6086
2. R.J. Albuquerque, T. Hayashi, W.G. Cho, M.E. Kleinman, S. Dridi, A. Takeda, J.Z. Baffi, K. Yamada, H. Kaneko, and M.G. Green Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth Nat. Med. 15 2009 1023 1030
3. B.K. Ambati, M. Nozaki, N. Singh, A. Takeda, P.D. Jani, T. Suthar, R.J. Albuquerque, E. Richter, E. Sakurai, and M.T. Newcomb Corneal avascularity is due to soluble VEGF receptor-1 Nature 443 2006 993 997
4. B.A. Appleton, P. Wu, J. Maloney, J. Yin, W.C. Liang, S. Stawicki, K. Mortara, K.K. Bowman, J.M. Elliott, and W. Desmarais Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding EMBO J. 26 2007 4902 4912
5. A.R. Aricescu, W. Lu, and E.Y. Jones A time- and cost-efficient system for high-level protein production in mammalian cells Acta Crystallogr. D Biol. Crystallogr. 62 2006 1243 1250
6. M.E. Baldwin, M.M. Halford, S. Roufail, R.A. Williams, M.L. Hibbs, D. Grail, H. Kubo, S.A. Stacker, and M.G. Achen Vascular endothelial growth factor D is dispensable for development of the lymphatic system Mol. Cell. Biol. 25 2005 2441 2449
7. Q. Cao, R.S. Mani, B. Ateeq, S.M. Dhanasekaran, I.A. Asangani, J.R. Prensner, J.H. Kim, J.C. Brenner, X. Jing, and X. Cao Coordinated regulation of polycomb group complexes through microRNAs in cancer Cancer Cell 20 2011 187 199
8. M. Caunt, J. Mak, W.C. Liang, S. Stawicki, Q. Pan, R.K. Tong, J. Kowalski, C. Ho, H.B. Reslan, and J. Ross Blocking neuropilin-2 function inhibits tumor cell metastasis Cancer Cell 13 2008 331 342
9. L.M. Ellis The role of neuropilins in cancer Mol. Cancer Ther. 5 2006 1099 1107
10. P. Emsley, B. Lohkamp, W.G. Scott, and K. Cowtan Features and development of Coot Acta Crystallogr. D Biol. Crystallogr. 66 2010 486 501
11. B. Favier, A. Alam, P. Barron, J. Bonnin, P. Laboudie, P. Fons, M. Mandron, J.P. Herault, G. Neufeld, and P. Savi Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration Blood 108 2006 1243 1250
12. R.E. Ferrell, M.A. Kimak, E.C. Lawrence, and D.N. Finegold Candidate gene analysis in primary lymphedema Lymphat. Res. Biol. 6 2008 69 76
13. M.L. Gagnon, D.R. Bielenberg, Z. Gechtman, H.Q. Miao, S. Takashima, S. Soker, and M. Klagsbrun Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity Proc. Natl. Acad. Sci. USA 97 2000 2573 2578
14. H.L. Goel, C. Chang, B. Pursell, I. Leav, S. Lyle, H.S. Xi, C.C. Hsieh, H. Adisetiyo, P. Roy-Burman, and I.M. Coleman VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer Cancer Discov. 2 2012 906 921
15. H.L. Goel, B. Pursell, C. Chang, L.M. Shaw, J. Mao, K. Simin, P. Kumar, C.W. Vander Kooi, L.D. Shultz, and D.L. Greiner GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation EMBO Mol. Med. 5 2013 488 508
16. K. Gordon, D. Schulte, G. Brice, M.A. Simpson, M.G. Roukens, A. van Impel, F. Connell, K. Kalidas, S. Jeffery, and P.S. Mortimer Mutation in vascular endothelial growth factor-C, a ligand for vascular endothelial growth factor receptor-3, is associated with autosomal dominant milroy-like primary lymphedema Circ. Res. 112 2013 956 960
17. P. Haiko, T. Makinen, S. Keskitalo, J. Taipale, M.J. Karkkainen, M.E. Baldwin, S.A. Stacker, M.G. Achen, and K. Alitalo Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos Mol. Cell. Biol. 28 2008 4843 4850
18. N.C. Harris, N. Davydova, S. Roufail, S. Paquet-Fifield, K. Paavonen, T. Karnezis, Y.F. Zhang, T. Sato, J. Rothacker, and E.C. Nice The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology J. Biol. Chem. 288 2013 8176 8186
19. Z. He, and M. Tessier-Lavigne Neuropilin is a receptor for the axonal chemorepellent Semaphorin III Cell 90 1997 739 751
20. J. Holash, S. Davis, N. Papadopoulos, S.D. Croll, L. Ho, M. Russell, P. Boland, R. Leidich, D. Hylton, and E. Burova VEGF-Trap: a VEGF blocker with potent antitumor effects Proc. Natl. Acad. Sci. USA 99 2002 11393 11398
21. D.I. Holmes, and I. Zachary The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease Genome Biol. 6 2005 209
22. J. Janin Wet and dry interfaces: the role of solvent in protein-protein and protein-DNA recognition Structure 7 1999 R277 R279
23. M. Jeltsch, A. Kaipainen, V. Joukov, X. Meng, M. Lakso, H. Rauvala, M. Swartz, D. Fukumura, R.K. Jain, and K. Alitalo Hyperplasia of lymphatic vessels in VEGF-C transgenic mice Science 276 1997 1423 1425
24. V. Joukov, K. Pajusola, A. Kaipainen, D. Chilov, I. Lahtinen, E. Kukk, O. Saksela, N. Kalkkinen, and K. Alitalo A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases EMBO J. 15 1996 1751
25. V. Joukov, T. Sorsa, V. Kumar, M. Jeltsch, L. Claesson-Welsh, Y. Cao, O. Saksela, N. Kalkkinen, and K. Alitalo Proteolytic processing regulates receptor specificity and activity of VEGF-C EMBO J. 16 1997 3898 3911
26. M.J. Karkkainen, R.E. Ferrell, E.C. Lawrence, M.A. Kimak, K.L. Levinson, M.A. McTigue, K. Alitalo, and D.N. Finegold Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema Nat. Genet. 25 2000 153 159
27. M.J. Karkkainen, A. Saaristo, L. Jussila, K.A. Karila, E.C. Lawrence, K. Pajusola, H. Bueler, A. Eichmann, R. Kauppinen, and M.I. Kettunen A model for gene therapy of human hereditary lymphedema Proc. Natl. Acad. Sci. USA 98 2001 12677 12682
28. M.J. Karkkainen, P. Haiko, K. Sainio, J. Partanen, J. Taipale, T.V. Petrova, M. Jeltsch, D.G. Jackson, M. Talikka, and H. Rauvala Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins Nat. Immunol. 5 2004 74 80
29. T. Karpanen, C.A. Heckman, S. Keskitalo, M. Jeltsch, H. Ollila, G. Neufeld, L. Tamagnone, and K. Alitalo Functional interaction of VEGF-C and VEGF-D with neuropilin receptors FASEB J. 20 2006 1462 1472
30. P.A. Karplus, and C. Faerman Ordered water in macromolecular structure Curr. Opin. Struct. Biol. 4 1994 770 776
31. R.L. Kendall, and K.A. Thomas Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor Proc. Natl. Acad. Sci. USA 90 1993 10705 10709
32. A.M. Khatib, R. Lahlil, N. Scamuffa, M.A. Akimenko, S. Ernest, A. Lomri, C. Lalou, N.G. Seidah, B.O. Villoutreix, and F. Calvo Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration PLoS One 5 2010 e11438
33. E. Kukk, A. Lymboussaki, S. Taira, A. Kaipainen, M. Jeltsch, V. Joukov, and K. Alitalo VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development Development 122 1996 3829 3837
34. V.M. Leppanen, A.E. Prota, M. Jeltsch, A. Anisimov, N. Kalkkinen, T. Strandin, H. Lankinen, A. Goldman, K. Ballmer-Hofer, and K. Alitalo Structural determinants of growth factor binding and specificity by VEGF receptor 2 Proc. Natl. Acad. Sci. USA 107 2010 2425 2430
35. V.M. Leppanen, D. Tvorogov, K. Kisko, A.E. Prota, M. Jeltsch, A. Anisimov, S. Markovic-Mueller, E. Stuttfeld, K.N. Goldie, and K. Ballmer-Hofer Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation Proc. Natl. Acad. Sci. USA 110 2013 12960 12965
36. M. Lohela, M. Bry, T. Tammela, and K. Alitalo VEGFs and receptors involved in angiogenesis versus lymphangiogenesis Curr. Opin. Cell Biol. 21 2009 154 165
37. A. Lymboussaki, B. Olofsson, U. Eriksson, and K. Alitalo Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia Circ. Res. 85 1999 992 999
38. T. Makinen, B. Olofsson, T. Karpanen, U. Hellman, S. Soker, M. Klagsbrun, U. Eriksson, and K. Alitalo Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1 J. Biol. Chem. 274 1999 21217 21222
39. B.K. McColl, M.E. Baldwin, S. Roufail, C. Freeman, R.L. Moritz, R.J. Simpson, K. Alitalo, S.A. Stacker, and M.G. Achen Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D J. Exp. Med. 198 2003 863 868
40. C. Miaskowski, M. Dodd, S.M. Paul, C. West, D. Hamolsky, G. Abrams, B.A. Cooper, C. Elboim, J. Neuhaus, and B.L. Schmidt Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery PLoS One 8 2013 e60164
41. M.H. Muders, H. Zhang, E. Wang, D.J. Tindall, and K. Datta Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1 Cancer Res. 69 2009 6042 6048
42. G.N. Murshudov Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
43. B. Olofsson, K. Pajusola, A. Kaipainen, G. von Euler, V. Joukov, O. Saksela, A. Orpana, R.F. Pettersson, K. Alitalo, and U. Eriksson Vascular endothelial growth factor B, a novel growth factor for endothelial cells Proc. Natl. Acad. Sci. USA 93 1996 2576 2581
44. B. Olofsson, K. Pajusola, G. von Euler, D. Chilov, K. Alitalo, and U. Eriksson Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform J. Biol. Chem. 271 1996 19310 19317
45. Z. Otwinowski, and W. Minor Processing of X-ray diffraction data collected in oscillation mode Macromol. Crystallogr. A 276 1997 307 326
46. M.W. Parker, and C.W. Vander Kooi Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions Anal. Biochem. 453 2014 4 6
47. M.W. Parker, L.M. Hellman, P. Xu, M.G. Fried, and C.W. Vander Kooi Furin processing of semaphorin 3F determines its antiangiogenic activity by regulating direct binding and competition for neuropilin Biochemistry 49 2010 4068 4075
48. M.W. Parker, H.F. Guo, X. Li, A.D. Linkugel, and C.W. Vander Kooi Function of members of the neuropilin family as essential pleiotropic cell surface receptors Biochemistry 51 2012 9437 9446
49. M.W. Parker, P. Xu, H.F. Guo, and C.W. Vander Kooi Mechanism of selective VEGF-A binding by neuropilin-1-reveals a basis for specific ligand inhibition PLoS One 7 2012 e49177
50. M.W. Parker, P. Xu, X. Li, and C.W. Vander Kooi Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1 J. Biol. Chem. 287 2012 11082 11089
51. M.W. Parker, A.D. Linkugel, and C.W. Vander Kooi Effect of C-terminal sequence on competitive semaphorin binding to neuropilin-1 J. Mol. Biol. 425 2013 4405 4414
52. S. Rose-John, and P.C. Heinrich Soluble receptors for cytokines and growth factors: generation and biological function Biochem. J. 300 1994 281 290
53. M. Rossignol, M.L. Gagnon, and M. Klagsbrun Genomic organization of human neuropilin-1 and neuropilin-2 genes: identification and distribution of splice variants and soluble isoforms Genomics 70 2000 211 222
54. A. Saaristo, M.J. Karkkainen, and K. Alitalo Insights into the molecular pathogenesis and targeted treatment of lymphedema Ann. N. Y. Acad. Sci. 979 2002 94 110
55. G. Siegfried, A. Basak, J.A. Cromlish, S. Benjannet, J. Marcinkiewicz, M. Chretien, N.G. Seidah, and A.M. Khatib The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis J. Clin. Invest. 111 2003 1723 1732
56. S. Soker, H. Fidder, G. Neufeld, and M. Klagsbrun Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain J. Biol. Chem. 271 1996 5761 5767
57. S. Soker, S. Takashima, H.Q. Miao, G. Neufeld, and M. Klagsbrun Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor Cell 92 1998 735 745
58. S.A. Stacker, K. Stenvers, C. Caesar, A. Vitali, T. Domagala, E. Nice, S. Roufail, R.J. Simpson, R. Moritz, and T. Karpanen Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates noncovalent homodimers J. Biol. Chem. 274 1999 32127 32136
59. S.A. Stacker, M.G. Achen, L. Jussila, M.E. Baldwin, and K. Alitalo Lymphangiogenesis and cancer metastasis Nat. Rev. Cancer 2 2002 573 583
60. M.J. Stanton, S. Dutta, H. Zhang, N.S. Polavaram, A.A. Leontovich, P. Honscheid, F.A. Sinicrope, D.J. Tindall, M.H. Muders, and K. Datta Autophagy control by VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance Cancer Res. 73 2012 160 171
61. A. Starzec, P. Ladam, R. Vassy, S. Badache, N. Bouchemal, A. Navaza, C.H. du Penhoat, and G.Y. Perret Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex Peptides 28 2007 2397 2402
62. M.W. Stewart Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug Br. J. Ophthalmol. 96 2012 1157 1158
63. E. Stuttfeld, and K. Ballmer-Hofer Structure and function of VEGF receptors IUBMB Life 61 2009 915 922
64. J.A. Tennessen, A.W. Bigham, T.D. O'Connor, W. Fu, E.E. Kenny, S. Gravel, S. McGee, R. Do, X. Liu, and G. Jun Evolution and functional impact of rare coding variation from deep sequencing of human exomes Science 337 2012 64 69
65. A.V. Timoshenko, S. Rastogi, and P.K. Lala Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells Br. J. Cancer 97 2007 1090 1098
66. C.W. Vander Kooi, M.A. Jusino, B. Perman, D.B. Neau, H.D. Bellamy, and D.J. Leahy Structural basis for ligand and heparin binding to neuropilin B domains Proc. Natl. Acad. Sci. USA 104 2007 6152 6157
67. M.A. von Wronski, N. Raju, R. Pillai, N.J. Bogdan, E.R. Marinelli, P. Nanjappan, K. Ramalingam, T. Arunachalam, S. Eaton, and K.E. Linder Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor J. Biol. Chem. 281 2006 5702 5710
68. Y. Xu, L. Yuan, J. Mak, L. Pardanaud, M. Caunt, I. Kasman, B. Larrivee, R. Del Toro, S. Suchting, and A. Medvinsky Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3 J. Cell Biol. 188 2010 115 130
69. L. Yuan, D. Moyon, L. Pardanaud, C. Breant, M.J. Karkkainen, K. Alitalo, and A. Eichmann Abnormal lymphatic vessel development in neuropilin 2 mutant mice Development 129 2002 4797 4806